{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:30:10Z","timestamp":1787689810543,"version":"build-2784847793"},"reference-count":0,"publisher":"ALUNA","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiadomo\u015bci Lekarskie"],"abstract":"<jats:p>Aim: To study the potential mechanisms underlying the beneficial nephroprotective effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors.\nMaterials and Methods: An analysis of literature sources was conducted regarding the clinical, epidemiological, and fundamental aspects of the nephroprotective\neffects of SGLT-2 inhibitors. For this purpose, articles were searched for and selected in the PubMed database using the following keywords: \u201csodium-glucose\ncotransporter-2 inhibitors,\u201d \u201cheart failure,\u201d \u201cchronic kidney disease,\u201d and \u201ccardiorenal syndrome,\u201d with a primary focus on studies published in the last 5 years.\nTo provide context and explain the underlying mechanisms, several classical and fundamental studies relevant to the aim of the review were also included.\nConclusions: SGLT-2 inhibitors exert nephroprotective effects through a complex of interrelated hemodynamic, metabolic, and cellular-molecular mechanisms\nthat are largely independent of their hypoglycemic action. The combination of these mechanisms explains the clinically proven nephroprotective effect of\nSGLT-2 inhibitors in both patients with and without DM and justifies considering them not only as glucose-lowering agents but also as fundamental agents of\npathogenetic therapy for chronic kidney disease.<\/jats:p>","DOI":"10.36740\/wlek\/220827","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T19:30:14Z","timestamp":1782675014000},"page":"1104-1110","source":"Crossref","is-referenced-by-count":1,"title":["Mechanisms of nephroprotective action of sodium\u2013glucose cotransporter type 2 inhibitors"],"prefix":"10.36740","author":[{"given":"\u041caryana \u041c.","family":"R\u043esul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u041cyroslava \u041c.","family":"Bletskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya V.","family":"Ivano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina O.","family":"Korabelschykova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2026,5,29]]},"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"link":[{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/pdf-220827-141708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/pdf-220827-141708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T19:30:22Z","timestamp":1782675022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/Mechanisms-of-nephroprotective-action-of-sodium-glucose-cotransporter-type-2-inhibitors,220827,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["220827"],"URL":"https:\/\/doi.org\/10.36740\/wlek\/220827","relation":{},"ISSN":["0043-5147","2719-342X"],"issn-type":[{"value":"0043-5147","type":"print"},{"value":"2719-342X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}